Prime Medicine (PRME) Depreciation & Amortization (CF) (2021 - 2026)

Prime Medicine (PRME) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 9.18% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 14.8% YoY) and the FY2025 annual result came in at $7.3 million, up 19.47% from the prior year.
• Depreciation & Amortization (CF) eased to $1.9 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q3 2025 to a low of $293000.0 in Q1 2022.
• A 5-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 279.91% — and 2026, when it increased 9.18%.
• Tracing PRME's Depreciation & Amortization (CF) over 5 years: stood at $870000.0 in 2022, then surged by 43.33% to $1.2 million in 2023, then jumped by 37.69% to $1.7 million in 2024, then rose by 9.26% to $1.9 million in 2025, then declined by 1.07% to $1.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.